Ionis Pharmaceuticals CEO Brett Monia Sells $8.5M in IONS Stock — Eight Insiders Unload $18.4M

Eight Ionis Pharmaceuticals insiders sold a combined $18.39 million in IONS stock in early 2026, led by CEO Brett P. Monia who sold $8.5 million. The selling spans the entire executive suite — from the CEO and CFO to the Chief Scientific Officer, General Counsel, and EVP Research.

Eight Sellers, $18.4M

Insider	Title	Transactions	Value	Shares After	Career Sales
Brett Monia	Chief Executive Officer	2	$8.50M	224,683	$46.0M
Eric Swayze	EVP Research	5	$2.54M	318	$7.2M
Elizabeth Hougen	EVP, Finance & CFO	2	$1.55M	126,307	$15.1M
Eugene Schneider	EVP, Chief Clinical Dev. Officer	2	$1.22M	63,890	$5.5M
Patrick O'Neil	EVP CLO & General Counsel	2	$1.21M	66,171	$35.0M
C. Frank Bennett	EVP, Chief Scientific Officer	2	$1.16M	94,757	$23.1M
Brian Birchler	EVP, Corp & Dev Ops	2	$1.15M	60,435	$4.0M
Joseph Baroldi	EVP, Chief Business Officer	3	$1.05M	4,772	$5.6M
Total: 8 insiders, 20 transactions			$18.39M

EVP Research Swayze: Down to 318 Shares

The most dramatic exit belongs to EVP Research Eric Swayze, who sold $2.54M across 5 transactions and was left with just 318 shares — worth approximately $15,000. For the executive responsible for Ionis's antisense RNA drug research pipeline, holding $15K in company stock is a near-complete exit. Swayze's $7.2M in career sales versus 318 remaining shares tells the story plainly.

CEO Monia: $46M Career Seller

Brett Monia has sold $46 million in IONS stock over his career. His $8.5M February sale leaves him with 224,683 shares (~$10.4M) — meaning he's sold more than 4x his current position. For the CEO of a biotech pioneer with over 50 antisense drugs in development, this ongoing liquidation program is extensive.

Legacy Scientists Cashing Out

Two of Ionis's most distinguished scientific leaders are also selling:

• Chief Scientific Officer Bennett ($23.1M career): The scientist behind Ionis's core antisense technology has sold $23M and retains 94,757 shares (~$4.4M). His career sales dwarf his remaining position by 5:1.
• General Counsel O'Neil ($35.0M career): With $35M in sales and 66,171 shares (~$3.1M) remaining, the CLO has sold more than 11x his current holdings.

The Antisense Pioneer

Ionis Pharmaceuticals is the leader in antisense RNA therapeutics — a revolutionary approach to treating diseases by targeting RNA molecules rather than proteins. The company has multiple FDA-approved drugs and a pipeline of over 50 candidates.

At ~$46 per share, IONS has a market cap of approximately $7 billion. The $18.4M in insider selling represents a small fraction of the float, but the breadth — 8 of 8 executives selling, including the scientific founders — suggests the leadership views current prices as a reasonable level to monetize.

Key Signal

When 8 out of 8 executives sell simultaneously, and the EVP of Research exits to 318 shares, the message is collective and clear. Ionis's leadership has been converting scientific value into personal liquidity for years — and the pace isn't slowing down. Combined career sales of $141.5 million across these eight insiders represent one of the deepest insider monetization programs in biotech.